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Abstract Using whole-cell patch clamp recording of hetero-
logous HERG-mediated currents in transfected mammalian cells,
we observed that the selective serotonin re-uptake inhibitor
citalopram blocks HERG with an IC50 of 3.97 WM. This is
slightly less potent than fluoxetine in our system (IC50 of 1.50
WM). In isolated guinea pig ventricular cardiomyocytes citalo-
pram inhibited L-type calcium current (ICa;L). The voltage
dependence of ICa;L inactivation in the presence of 100 WM
citalopram was shifted significantly leftward. As a result, the
ICa;L ‘window’ in citalopram was found to be (a) smaller and
(b) leftward-shifted compared to control. The effects of
citalopram on both calcium current amplitude and the ICa;L
‘window’ may help to explain citalopram’s good cardiac safety
profile, given its propensity to block HERG at excessive
dosages. ß 2002 Federation of European Microbiological So-
cieties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
In cases of self-poisoning by a single agent, tricyclic anti-
depressants (TCAs) are associated with higher fatal toxicity
indices than are selective serotonin re-uptake inhibitors
(SSRIs), and this is presumably due to QT prolongation of
the electrocardiogram (ECG) and the associated arrhythmo-
genesis that can accompany TCA overdose [1^4]. Within the
clinical concentration range, TCA use, but not SSRI use, is a
signi¢cant risk factor for lengthening of the QT interval of the
ECG in psychiatric patients [5], and SSRIs are thought to be
safer than TCAs in the background of cardiovascular risk [6].
Citalopram is an SSRI that has similar e⁄cacy against depres-
sion to other SSRIs, and to tetracyclic antidepressants and
TCAs [7]. In contrast to TCAs, citalopram is reputed to
have a good safety pro¢le at concentrations within the clinical
range [7,8] ; therefore, citalopram may be an attractive agent
for treatment of patients who cannot tolerate the cardiovas-
cular adverse e¡ects of TCAs or who su¡er comorbid illness
that also requires drug treatment. However, considerable con-
troversy has arisen over the possible e¡ects of citalopram in
overdose, particularly with regard to QT prolongation and
potential arrhythmogenic risk [9^13].
The risk of QT prolongation and associated arrhythmia by
TCAs corresponds at the cellular level with pharmacological
inhibition of native cardiac delayed recti¢er potassium (K)
channels [14] and current carried by the cloned K subunit
mediating the rapid delayed recti¢er current ^ HERG [15].
TCAs such as imipramine and amitriptyline inhibit HERG
channels at clinically relevant concentrations [16^18]. The ac-
tions of SSRIs such as citalopram on HERG channels have
not yet been reported. The reported safety pro¢le of the agent
might lead to a prediction that HERG channels are insensitive
to citalopram. The aim of the present study was to test this
experimentally, using heterologously expressed HERG K
channels. We report here that HERG is sensitive to inhibition
by citalopram. However, we also found that this drug can
inhibit cardiac L-type calcium (Ca2) current (ICa;L), and it
is possible that this e¡ect may o¡set QT prolongation and the
associated pro-arrhythmia that would otherwise occur as a
result of selective HERG blockade.
2. Materials and methods
2.1. Transient expression of HERG
The transient expression of HERG was performed using Chinese
hamster ovary (CHO) cells that were maintained as described previ-
ously [19]. In brief, cDNA encoding the HERG channel subunit was
subcloned into pGW1H, which contains a CMV promoter to drive
expression of the insert. Cells were plated onto small sterilised glass
coverslips and after 24 h the cells were co-transfected with 3:1 HERG
cDNA:green £uorescent protein (GFP) in pCMX using the recom-
mended lipofectamine (BRL) protocol. Cells were washed with Opti-
mem (BRL) medium, and after a 45 min incubation together, a mix-
ture including 6 Wl lipofectamine solution with 1 Wg total plasmid
DNA was added to cells in a 30 mm petri dish, followed by a 4 h
incubation before the reintroduction of 10% (¢nal) foetal bovine se-
rum. Between 20 and 36 h after transfection coverslips were trans-
ferred to the recording chamber. Additional measurements were made
from a human embryonic kidney cell line (HEK 293) stably expressing
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HERG and maintained as previously described [20]; some small dif-
ferences in the recording conditions (described below) of the two types
of cells were made, which led to increased cell longevity during re-
cording for each type of cell. No statistical di¡erence between citalo-
pram blockade of HERG (tail current maximum at 340 mV) in the
two heterologous systems in the two sets of recording conditions was
observed at the two concentrations tested (3 WM and 100 WM; un-
paired t-test, Ps 0.2 for both, n = 3^8).
2.2. Guinea pig isolated ventricular myocytes
Myocytes were isolated from both ventricles of male guinea pig
(V400 g) hearts, using an enzymatic dispersion method described
previously [21]. The cells were stored at room temperature in solution
containing 1 mM Ca2 until required for use. Cells remained viable
for up to 8 h after isolation.
2.3. Electrophysiological recording
2.3.1. HERG current (IHERG) measurement in transiently transfected
cells. Whole-cell patch clamp recordings were made at 20‡C in nor-
mal Tyrode’s solution containing (in mM): 140 NaCl, 4 KCl, 2 CaCl2,
1 MgCl2, 10 glucose, 5 HEPES (titrated to a pH of 7.4 with NaOH).
Citalopram (Lundbeck) was added to this solution to the ¢nal con-
centrations mentioned in the text from a 30 mM stock solution made
daily in de-ionised (Milli-Q) water. Patch pipettes (1.5 mm o.d. soda
glass; Harvard Apparatus) were pulled to resistances of 4^5 M6. The
K-based internal dialysis solution contained (in mM): 144 KCl,
8 Na2HPO4, 2 NaH2PO4, 1 Na2ATP, 0.3 Na2GTP, 2 MgCl2,
0.5 EGTA (pH to 7.3 with KOH).
Membrane current recordings were made using List EPC-7 patch
clamp ampli¢ers (Heka Elektronik). Current and voltage were
sampled at rates between 1 and 20 kHz using a standard laboratory
Fig. 1. Citalopram blocks HERG-mediated current. (A) shows representative current records from a cell before and after addition of 30 WM
citalopram. After stable control recordings (hold 380 mV, step to +20 mV for 2 s, observe tail currents at 340 mV, a schematic of the voltage
protocol is shown at the top of (A)) were attained, citalopram was superfused onto the cell for 2 min while the cell was held at 380 mV. Then
the above protocol was repeated until blockade reached steady-state. (B) shows the means þ S.E.M. of a series of the same experiment, in which
di¡erent concentrations of either citalopram (open triangles) or £uoxetine (closed squares) were applied to the cell. These were then ¢tted to a
logistic equation. (C^F) show the voltage dependence of citalopram blockade of IHERG. Cells expressing heterologous HERG were held at
380 mV and stepped to di¡erent voltages (350 mV to +30 mV, 10 mV steps) for 2 s, and then tail currents were measured at 340 mV for 4 s
(‘IV protocol’ ; minimum 10 s interpulse interval). The cells were then allowed to equilibrate with 10 WM citalopram for 3^5 min while held at
380 mV. The cells were then stepped repeatedly to +20 mV (using the protocol in (A)) in the presence of citalopram until blockade reached
equilibrium, after which the cells were subjected to the IV protocol again. (C) and (D) are examples of typical current records from one cell,
control (C), 10 WM citalopram (D). Some of the individual traces in (C) are labelled with their depolarising test potentials (in mV) for clarity.
(E) shows the IV relation for the peak tail currents (IHERG) recorded during the step to 340 mV for the same representative cell. In (F) the
average percentage of IHERG blockade was calculated by subtracting the ratio of current with and without citalopram at a single voltage from
unity for each cell before calculating the mean for all cells. n = 5.
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interface (1401Plus, Cambridge Electronic Design) controlled by cus-
tomised software [22]. Normally 75^80% of the electrode series resis-
tance could be compensated.
2.3.2. IHERG measurement in stably transfected cells. Methodolo-
gies and protocols for the stable cell line were identical to those of the
transiently transfected cells with the following changes. Pipette glass
used was Corning 7052 glass (AM Systems Inc.), and these were
initially pulled to resistances of 2^3 M6 and then ¢re-polished to
4^5 M6. Recordings were made at 35^37‡C using a K-based internal
dialysis solution containing (in mM): 110 KCl, 5 K2ATP, 0.4 MgCl2,
5 EGTA, 10 HEPES (titrated to pH 7.1 by adding KOH). The am-
pli¢er used was an Axopatch 1D ampli¢er (Axon Instruments) with a
CV-4 1/100 headstage. Voltage clamp commands were generated using
‘WinWCP’, a program written and supplied free of charge by John
Dempster (Strathclyde University) and data were recorded via a Digi-
data interface. The HERG-expressing HEK 293 stable cell line pro-
vided essentially identical results to the HERG transiently transfected
CHO cells (see above).
2.3.3. ICa;L measurement. A Cs-based internal dialysis solution
was used for all ICa;L recordings; its composition was as follows (in
mM): 113 CsCl, 5 K2ATP, 0.4 MgCl2, 2 K2EGTA, 5 glucose, 10
HEPES, titrated to pH 7.2 with CsOH. Isolated myocytes were
bathed in a normal Tyrode’s solution at 35^37‡C until whole-cell
clamp had been obtained, after which ‘control’ solution was applied
(standard Tyrode’s solution, free of external K, in order to inhibit
inwardly rectifying K current). Citalopram was added to this solu-
tion to the ¢nal concentrations mentioned in the text from a stock
solution as described above. An Axopatch 200B ampli¢er, with a CV
202A headstage was used for all ICa;L recordings. Pulse protocols were
generated and membrane currents recorded using pCLAMP 7.0.
2.4. Data analysis and presentation
Data were analysed o¥ine, using WinWCP, pCLAMP (Clamp¢t),
Excel 5.0 and ‘FigP for Windows’ (Biosoft). Data are presented as
mean þ S.E.M. and statistical comparisons were made using a paired
Student’s t-test (Systat, Systat Inc.). P values of 6 0.05 were taken as
signi¢cant.
3. Results
3.1. E¡ects of citalopram on IHERG
The e¡ects of citalopram upon outward current associated
with expression of the HERG transcript in mammalian cells
were tested, without pharmacological inhibitors in either the
external or pipette solutions, in the whole-cell mode of patch
clamp. These cells have previously been shown to lack IHERG
when untransfected [16,20]. The membrane potential was held
at 380 mV, and interpulse intervals were a minimum of 6 s to
allow complete deactivation of the channel to occur between
sweeps. To test the e¡ect of citalopram on IHERG, a 2 s step to
+20 mV was used to activate (and inactivate) the current, and
then tail currents were measured at 340 mV to allow for
rapid recovery from inactivation; the peak of the tail current
(IHERG) was compared in the presence and absence of di¡erent
concentrations of citalopram. In Fig. 1A a representative ex-
periment comparing the current in normal Tyrode’s solution
(control) and in the presence of 30 WM citalopram is shown;
the block was profound, with 86.6 þ 5.1% of IHERG being
blocked at this concentration (n = 7); this concentration is
well above the maximum plasma concentration of 120 ng/ml
(nominally a maximum of 300 nM, ignoring drug binding)
observed at the therapeutic dosages [8], but it may occur in
cases of self-poisoning.
A series of citalopram concentrations were compared to
control in order to determine the concentration response rela-
tionship for citalopram blockade of IHERG, and this is shown
in Fig. 1B. At 100 WM, the highest concentration attempted,
IHERG was blocked 90.0 þ 1.8% (n = 9), and the data were ¢t-
Fig. 2. Time dependence of citalopram blockade of IHERG. Cells ex-
pressing heterologous HERG were held at 380 mV and stepped to
0 mV for 10 s. The cells were then allowed to equilibrate with either
1 WM E-4031 or 10 WM citalopram for 3^5 min while being held at
380 mV. The cells were then subjected to the same command pro-
tocol again. (A) shows a representative current record in the pres-
ence and absence of E-4031. (B^D) show experiments using 10 WM
citalopram. (B) is a representative set of traces, and (C) shows the
percentage IHERG remaining (i.e. the ratio of current to current
without citalopram) at each time point, and then the mean calcu-
lated for ¢ve cells during the ¢rst 2 s of the long pulse protocol.
(D) shows that the block does not change after 3 s; for each cell at
each 1 s interval a mean of current measured over 20 ms is calcu-
lated in the presence and absence of citalopram, and the percentage
block for that time point is then calculated. The graph shows the
means for ¢ve cells of the percentage block.
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ted by computer to a logistic equation. The observed IC50 was
3.97 WM, and the Hill coe⁄cient was 0.75 (n = 5^10 for all
concentrations); this Hill coe⁄cient may suggest that there
was a one-to-one interaction between drug molecule and
channel. This potency of IHERG block is not dissimilar from
that observed in our experimental system when testing the
TCA imipramine: IC50 = 3.4 WM and nHill = 1.17 [16].
3.2. Fluoxetine blockade of IHERG
Measurements of IHERG blockade by £uoxetine, an SSRI
with a fatal toxicity index 50-fold lower than imipramine
[1], were made to allow for a direct comparison of the two
drugs’ abilities to block IHERG in a single experimental sys-
tem; experiments and protocols were as per citalopram above,
and the results are shown in Fig. 1B. The observed IC50 for
£uoxetine was 1.50 WM, and the Hill coe⁄cient was 0.79
(n = 4^9 for all concentrations); again this Hill coe⁄cient
may suggest that there was a one-to-one interaction between
drug molecule and channel. This observed IC50 for £uoxetine
in our system is similar to that reported recently (1.0 WM) in
abstract form, where the experimenters used CHO cells trans-
fected with HERG [23]. Our data suggest that £uoxetine is a
slightly more potent blocker of IHERG than is citalopram; the
di¡erence in the block potency between £uoxetine and citalo-
pram was statistically signi¢cant (unpaired t-test, P6 0.01
and P6 0.05 at 1 and 10 WM of the drugs, respectively,
n = 5^8).
3.3. Voltage e¡ects on citalopram blockade of IHERG
In order to characterise further the mechanism of citalo-
pram’s blockade of IHERG, individual cells were subjected to
a series of voltage commands in which the test pulse voltage
(lasting 2 s) varied between 350 mV and +30 mV in incre-
ments of 10 mV, and after each test potential the tail current
was observed at 340 mV. This protocol was then repeated in
the presence of 10 WM citalopram. Data from a representative
experiment are shown in Fig. 1C,D. The maximum tail cur-
rent was plotted for each voltage (shown in Fig. 1E for the
same cell as in Fig. 1C,D), and then the percentage of HERG
tail current blocked by 10 WM citalopram was calculated for
each cell at each voltage, and the mean for each voltage was
plotted in Fig. 1F. Some voltage dependence of block was
detected at voltages below 0 mV, which may be indicative
of open-state dependence of block, although the trend to-
wards voltage dependence did not attain statistical signi¢cance
(analysis of variance (ANOVA), between groups,
F(7,37) = 1.96, P = 0.087).
3.4. Time course of blockade
It has been shown previously that methanesulphonanilides
(e.g. MK-499, E-4031) are associated with an open-state-de-
pendent blockade of HERG (e.g. [24]), and this manifests
itself during long pulse protocols with increasing blockade
observed over the course of seconds [20]. An example of the
blockade by 1 WM E-4031 over time during a 10 s voltage step
to 0 mV is shown in Fig. 2A. By comparison, the time course
of blockade by citalopram during a long pulse does not dem-
onstrate the same kind of time dependence. Current traces for
a typical experiment are shown in Fig. 2B. A mean of the
ratios of current in the presence and absence of citalopram
(Fig. 2C) suggests that the block showed statistically signi¢-
cant time dependence early during an applied depolarisation
(ANOVA, F(9,465) = 2.45, P = 0.01). However, mean data
plotted between 1 and 10 s (Fig. 2D) showed no signi¢cant
di¡erence in level of blockade after approximately the ¢rst
second (ANOVA, F(9,40) = 0.26, P = 0.98). These data are
consistent with an activation-dependent blockade of IHERG
by citalopram, but that this occurred with dramatically di¡er-
ent kinetics from that commonly associated with methanesul-
phonanilides.
3.5. E¡ects of citalopram on ICa;L
It is known that e¡ects of inhibition of rapid delayed rec-
ti¢er K current can be o¡set by concomitant drug e¡ects on
opposing, inwardly directed current ^ in particular ICa;L
[25,26]. We hypothesised, therefore, that in addition to a¡ect-
ing IHERG, citalopram might also modulate cardiac ICa;L.
Therefore, the e¡ects of citalopram on ICa;L were investigated,
by measuring ICa;L from guinea pig isolated ventricular
myocytes (see Section 2), and by using similar voltage
clamp protocols to those employed recently by Hobai et al.
[27].
Fig. 3A shows the e¡ect of 100 WM citalopram on peak
ICa;L elicited by a test pulse to +10 mV. In each of seven cells,
application of this concentration of citalopram led to a de-
crease in ICa;L amplitude, with a mean percentage inhibition of
64.95 þ 2.34%. In order to ascertain whether or not this alter-
ation in amplitude was accompanied by a change in time
course of ICa;L during sustained depolarisation, the time
course of the current was ¢tted to a biexponential decline:
ICa;Lt  A1 exp3t=d 1  A2 exp3t=d 2  C 1
where A1 and A2, and d1 and d2 are the maximal amplitudes
and time constants of the two exponentials, respectively, C is
any residual current component and t is time. The e¡ects of
citalopram on the fast and slow time constants of inactivation
are shown in Fig. 3B. Neither time constant was signi¢cantly
a¡ected by citalopram (Ps 0.1; n = 7 cells). Thus, citalopram
reduced ICa;L amplitude without signi¢cantly a¡ecting the in-
activation time course of the current.
Inhibition of ICa;L by citalopram was concentration-depen-
dent. The e¡ects of citalopram concentrations between 1 and
100 WM were tested, and the resulting mean ( þ S.E.M.) frac-
tional inhibition values were plotted against concentration as
shown in Fig. 3C. The inhibitory action of citalopram against
ICa;L was less potent than that against IHERG (cf. Fig. 3A with
Fig. 1B).
The characteristics of inhibition by citalopram of ICa;L were
examined further by studying the drug’s action on ICa;L elic-
ited at di¡erent test voltages between 340 and +50 mV. Fig.
4A shows that 100 WM citalopram inhibited ICa;L across the
range of test potentials. In order to determine the e¡ects of
the agent on the voltage-dependent activation parameters for
ICa;L, the ICa;L^V relations in control and drug were ¢tted by a
modi¢ed Boltzmann relation:
ICa;L  GmaxVm3V rev=f1 expV0:53Vm=kg 2
where V0:5 and k are the half maximal activation membrane
potential and the slope of the curve, respectively, Gmax is
maximal ICa;L conductance and Vrev is the reversal potential
for ICa;L extrapolated from the linear portion of the ascending
limb of the I^V relation. Values for V0:5 in control and
FEBS 25700 8-2-02
H.J. Witchel et al./FEBS Letters 512 (2002) 59^6662
citalopram from each of six cells were pooled, in order to
determine and compare mean þ S.E.M. parameters. In con-
trol, V0:5 and k were 310.95 þ 1.91 mV and 6.01 þ 0.19 mV,
respectively; whilst in citalopram the V0:5 mean k values were
312.80 þ 1.19 mV and 6.21 þ 0.29 mV, respectively. Neither
V0:5 nor k was statistically signi¢cantly altered by citalopram
(Ps 0.2 in each case).
The e¡ect of citalopram on the voltage dependence of in-
activation of ICa;L was determined using the protocol shown
in Fig. 4B (inset). An initial pulse elicited an ICa;L current; this
was followed by conditioning pulses to a range of voltages, in
order to produce di¡erent levels of ICa;L inactivation. The
conditioning pulses were then followed by a test pulse to
+10 mV. ICa;L during the test pulse following conditioning
pulses to di¡ering potentials was expressed as a proportion
of the maximal ICa;L value obtained, and plotted against the
corresponding conditioning voltage. The resulting plots for
each of eight cells were ¢tted by a Boltzmann function:
ICa;L=ICa;Lmax  131=f1 expV0:53Vm=kg 3
where ICa;Lmax is maximum ICa;L. By pooling values for both
V0:5 and k for both control solution and in 100 WM citalo-
pram, the mean values for control V0:5 and k were found to
be: 326.97 þ 1.43 mV and 4.09 þ 0.08 mV, respectively. In the
presence of citalopram V0:5 and k were 352.71 þ 2.40 mV and
8.22 þ 0.50 mV, respectively. The alterations to both V0:5 and
k values were signi¢cant (P6 0.001).
Arrhythmias arising from HERG channel blockade are be-
lieved to correlate at the cellular level with early afterdepolar-
isations (EADs), events that arise due to increased Ca2 entry
as the membrane potential scans the ICa;L ‘window’ during
Fig. 3. Citalopram inhibits ventricular ICa;L. A: Upper traces show representative ionic currents elicited by the voltage protocol illustrated in
the lower traces. After a pre-pulse to 340 mV, a test pulse to +10 mV elicited ICa;L. The amplitude of ICa;L in the presence of 100 WM citalo-
pram (right panel) was reduced compared to that in control (left panel). Bar charts (B) show e¡ects of citalopram on the magnitudes of fast
(df ^ left panel) and slow (ds ^ right panel) time constants of inactivation of ICa;L determined using Eq. 2 (see text). Neither time constant was
signi¢cantly altered by citalopram. In (C) the bar chart shows the concentration dependence of ICa;L inhibition (shown as ‘fractional inhibition’)
between 1 and 100 WM citalopram.
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action potential repolarisation [28,29]. Using V0:5 and k values
obtained from the I^V ¢ts (Fig. 4A) and inactivation curve
plots (Fig. 4B), we were able to simulate the e¡ects of citalo-
pram on the ICa;L ‘window’, as follows: the inactivation pa-
rameters were simulated at 2 mV intervals between 3100 mV
and +20 mV using Eq. 3, and activation parameters were
simulated using the equation:
Activation variable  1=1 expV0:53Vm=k 4
where ‘activation variable’ at any test potential Vm occurs
within the range 0^1; V0:5 and k have similar meanings to
those in Eq. 2. For both conditions, the area of overlap of
activation and inactivation curves in Fig. 4C denotes the ICa;L
window region ^ a potential range over which a small persis-
tent Ca2 entry would be anticipated. Thus, in the simulated
presence of citalopram, the ICa;L ‘window’ was both smaller
than that in control, and was shifted towards more negative
potentials ^ both e¡ects likely attributable to the alterations in
voltage-dependent inactivation kinetics of the current.
Collectively, our ¢ndings regarding ICa;L are indicative of a
direct interaction between citalopram with the ICa;L channel
Fig. 4. E¡ect of citalopram on voltage-dependent properties of ICa;L. A: Current^voltage (I^V) relations for ICa;L in control and 100 WM citalo-
pram. ICa;L density (pA/pF) values were obtained at potentials between 340 and +50 mV, and were pooled to produce mean values from six
cells. For each condition, the mean data were ¢tted by a modi¢ed Boltzmann equation (control: V0:5 =312.56 mV, k = 5.58 mV; citalopram:
V0:5 =313.92, k = 6.20 mV). B: Plots of steady-state inactivation curves for ICa;L in control and in 100 WM citalopram. Voltage protocol shown
in inset. Data from each of eight cells were pooled, to give mean þ S.E.M. values for the inactivation variable at each potential. The plots in
control and drug were ¢tted by Eq. 3 (see Section 3). Control: V0:5 =326.90 mV, k = 4.74 mV; citalopram: V0:5 =352.45, k = 8.94 mV.
C: ICa;L ‘window’, simulated for control and citalopram. Activation parameters were simulated at 2 mV intervals between 3100 and +20 mV,
using Eq. 4. The mean V0:5 and k values obtained by pooling the values obtained from ¢ts to individual cells were used (control: 310.95 mV
and 6.01 mV, for V0:5 and k, respectively; citalopram: 312.80 mV and 6.21 mV for V0:5 and k, respectively). Inactivation parameters were also
simulated at 2 mV intervals on the basis of parameters derived from pooling V0:5 and k values for individual cells (control: 326.97 mV and
4.09 mV for V0:5 and k, respectively; citalopram: 352.71 mV and 8.22 mV, respectively). For each condition, the area of overlap of the activa-
tion and inactivation curves denotes the ICa;L window.
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that (a) resulted in decreased £ow of ICa;L across a range of
test potentials, (b) altered voltage-dependent inactivation ki-
netics, without an altered inactivation time course of the cur-
rent (c) would have decreased steady-state Ca2 entry over the
range of window voltages. Previous data for ICa;L block by the
SSRI £uoxetine using conventional microelectrodes and
whole-cell patch clamp of guinea pig and rabbit papillary
muscles and single canine ventricular myocytes are consistent
with conclusions (a) and (b) [30], although they did not di-
rectly investigate ‘window’ ICa;L.
4. Discussion
The foregoing data indicate that IHERG is sensitive to inhi-
bition by citalopram. In our heterologous mammalian system
the potency of citalopram’s block is similar to that of imi-
pramine and amitriptyline [16], but the potency of £uoxetine
is stronger than that of all three other antidepressants. The
mechanism of block by citalopram can be distinguished from
that of E-4031 with a long pulse protocol, in that substantially
less current is blocked initially by E-4031 when the ¢rst de-
polarising pulse in the presence of drug is applied, even
though the percentage block that develops later in 1 WM
E-4031 far exceeds the block by 10 WM citalopram. Using a
similar protocol, the mechanism of imipramine can be distin-
guished from that of citalopram in that the imipramine block
appears in part almost immediately, and may have a compo-
nent of closed-state block [16].
In cardiomyocytes, the block by citalopram of native cur-
rents mediated by HERG would reduce net repolarising cur-
rent. In turn, this would be expected to result in ventricular
action potential prolongation, and thereby would lead to pro-
longation of the QT interval of the ECG and the associated
risk of Torsades de pointes [31]. However, the reported safety
pro¢le for citalopram [7,8] has not been suggestive of this as a
major risk factor in citalopram use. This is consistent with the
existence of an additional drug action, a¡ecting a depolarising
current that modulates the action potential plateau duration,
such as ICa;L.
After commencement of citalopram treatment, in 277 pa-
tients with pre-existing heart disease or on drug therapy with
agents known to have the potential for QTc prolongation, no
further prolongation of QTc was detected [9]. By contrast to
the situation at therapeutic dosages, in Sweden a forensic
analysis of six suicides concluded that suicidal citalopram
overdose was associated with the deaths, and no other modes
of death could be found by forensic investigation [11]. Anoth-
er report of ¢ve citalopram-mediated attempted suicides in
Sweden showed that all patients had a prolonged QT interval
[12]. However, the Swedish Poisons Information Centre ana-
lysed 108 cases of acute citalopram overdose and concluded
that most cases have an uneventful course and that clinically
signi¢cant arrhythmias are rare [13]. Since that time, citalo-
pram has been released in the USA, and the low incidence of
reported abnormalities might result either from the fact that
drug has not been released for as long as have TCAs, or from
channel e¡ects that o¡set the IHERG blockade. An example of
the latter situation is verapamil, a calcium channel blocker
that blocks HERG at submicromolar concentrations [32]
but is not associated with QT prolongation [25,26].
It is di⁄cult to predict from in vitro experiments the dom-
inant e¡ect of a drug on arrhythmogenic risk in vivo. Despite
citalopram mediating a more potent block of IHERG than of
ICa;L, the overall e¡ect may depend on the relative contribu-
tions of the two currents to the ventricular action potential
pro¢le at particular rates. Intriguingly, in conventional micro-
electrode experiments on guinea pig papillary muscle, citalo-
pram has been shown to cause a shortening, rather than a
lengthening, of action potential duration [33]. The e¡ect of
citalopram on ICa;L may be su⁄cient to either o¡set the QT
prolongation associated with IHERG blockade, or even if mod-
est it may be su⁄cient to minimise the likelihood of EAD
generation that would contribute to arrhythmogenesis
[34,28]. As shown in Fig. 4, the ICa;L window in these experi-
ments is (a) smaller and (b) leftward-shifted in citalopram
compared to control. Thus, citalopram (i) decreases ICa;L am-
plitude, which might o¡set to an extent QT prolongation and
(ii) produces a smaller window and at more negative poten-
tials ^ these e¡ects may reduce the likelihood of EADs
through ICa;L reactivation, even if QT prolongation were to
occur.
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